285 related articles for article (PubMed ID: 29296803)
21. [Bone marrow fibrosis in primary myelofibrosis in relation to myelodysplasia- and age-related mutations of hematopoietic cells].
Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
Pathologe; 2020 Dec; 41(Suppl 2):124-128. PubMed ID: 33113046
[TBL] [Abstract][Full Text] [Related]
22. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
[TBL] [Abstract][Full Text] [Related]
23. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
[TBL] [Abstract][Full Text] [Related]
24. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
25. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
26. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
27. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jan; 92(1):56-61. PubMed ID: 27733013
[TBL] [Abstract][Full Text] [Related]
28. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
29. Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.
Lee YC; Hsieh CC; Lee YL; Li CY
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):558-568. PubMed ID: 29970342
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
31. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
[TBL] [Abstract][Full Text] [Related]
32. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Kandarpa M; Wu YM; Robinson D; Burke PW; Chinnaiyan AM; Talpaz M
Am J Hematol; 2017 Jun; 92(6):555-561. PubMed ID: 28335073
[TBL] [Abstract][Full Text] [Related]
35. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
36. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
Tefferi A; Guglielmelli P; Nicolosi M; Mannelli F; Mudireddy M; Bartalucci N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Begna KH; Naseema Gangat ; Pardanani A; Vannucchi AM
Leukemia; 2018 Jul; 32(7):1631-1642. PubMed ID: 29654267
[TBL] [Abstract][Full Text] [Related]
37. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.
McClure RF; Ewalt MD; Crow J; Temple-Smolkin RL; Pullambhatla M; Sargent R; Kim AS
J Mol Diagn; 2018 Nov; 20(6):717-737. PubMed ID: 30138727
[TBL] [Abstract][Full Text] [Related]
39. Coexistence of Primary Myelofibrosis and Paroxysmal Nocturnal Hemoglobinuria Clone with
Park S; So MK; Cho MS; Kim DY; Huh J
Diagnostics (Basel); 2021 Sep; 11(9):. PubMed ID: 34573985
[TBL] [Abstract][Full Text] [Related]
40. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]